NIKKEI 225
39,173.15 +368.50 (+0.95%) HANG SENG
18,081.35 +53.64 (+0.30%) CRUDE OIL
81.70 +0.07 (+0.09%) GOLD FUTURES
2,336.40 -8.00 (-0.34%) DOW
39,411.21 +260.91 (+0.67%) Bitcoin GBP
48,099.04 -998.25 (-2.03%)
ILMN Jul 2024 155.000 put
| Previous close | 49.26 |
| Open | 49.26 |
| Bid | 42.00 |
| Ask | 50.60 |
| Strike | 155.00 |
| Expiry date | 2024-07-05 |
| Day's range | 49.26 - 49.26 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Reuters
Grail bets big on flagship cancer test after spin-off from Illumina
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina, is betting that commercial partnerships with health systems, employers and life insurance companies of its flagship cancer-detection test will power its near-term growth as an independent company. The blood test, called Galleri, can detect multiple types of cancer early and looks for 80% of the cancers that are currently not screened for, Grail CEO Bob Ragusa said in a telephone interview on Monday. Ragusa estimates there are about 100 million people in the U.S. that are at elevated risk of being diagnosed with cancer, with another 90 million in the UK, 160 million across the EU and almost 50 million in Japan.
PR NewswireIllumina completes the divestiture of GRAIL
Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. GRAIL will begin regular way trading on Nasdaq on Tuesday, June 25 under the ticker symbol "GRAL." Illumina will continue to trade on Nasdaq under the ticker symbol "ILMN."
ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
